- Q2 2024 Teijin Ltd Earnings Presentation TranscriptNov 06, 2023
- Q1 2024 Teijin Ltd Earnings Presentation TranscriptAug 07, 2023
- Full Year 2023 Teijin Ltd Earnings Presentation TranscriptMay 11, 2023
- Q3 2023 Teijin Ltd Earnings Presentation TranscriptFeb 08, 2023
- Q2 2023 Teijin Ltd Earnings Presentation TranscriptNov 07, 2022
- Q1 2023 Teijin Ltd Earnings Presentation TranscriptAug 08, 2022
- Teijin Ltd Business Outlook TranscriptJun 03, 2022
- Full Year 2022 Teijin Ltd Earnings Presentation TranscriptMay 12, 2022
- Teijin Ltd ESG Briefing TranscriptFeb 17, 2022
- Q3 2022 Teijin Ltd Earnings Presentation TranscriptFeb 07, 2022
- Teijin Ltd Regenerative Medicine Business Briefing TranscriptDec 02, 2021
- Q2 2022 Teijin Ltd Earnings Presentation TranscriptNov 08, 2021
- Q1 2022 Teijin Ltd Earnings Presentation TranscriptAug 06, 2021
- Teijin Ltd Business Overview Presentation TranscriptJun 02, 2021
- Full Year 2021 Teijin Ltd Earnings Presentation TranscriptMay 11, 2021
- Teijin Ltd Healthcare Business Field Presentation TranscriptApr 07, 2021
- Q3 2021 Teijin Ltd Earnings Presentation TranscriptFeb 08, 2021
- Q2 2021 Teijin Ltd Earnings Presentation TranscriptNov 02, 2020
- Q1 2021 Teijin Ltd Earnings Presentation TranscriptAug 05, 2020
- Full Year 2020 Teijin Ltd Earnings Presentation TranscriptMay 08, 2020
- Q3 2020 Teijin Ltd Earnings Presentation TranscriptFeb 05, 2020
- Q2 2020 Teijin Ltd Earnings Presentation TranscriptNov 01, 2019
- Q1 2020 Teijin Ltd Earnings Presentation TranscriptAug 02, 2019
- Full Year 2019 Teijin Ltd Earnings Presentation TranscriptMay 09, 2019
Teijin Ltd Regenerative Medicine Business Briefing Transcript
This is Jun Suzuki of Teijin. Thank you for joining us in our regenerative medicine business briefing today. It gives us a great pleasure to have so many participants.
As you are aware, on January 29 of this year, Teijin announced the Board decision to acquire the shares in J-TEC through a tender offer. The stock purchase was carried out from February 1 to March 2 and was successfully completed as originally planned, making Teijin the parent company of J-TEC. Following the closing in March, we embarked on more detailed official studies on how best to improve the corporate value of both Teijin and J-TEC.
When we made the internal decision to join hands with J-TEC more than a year ago, we already had a clear vision regarding the direction of the business that is to pursue regenerative medicine using autologous cell as the alternate of tailor-made medicine. Furthermore, we did envision that this business could make the big leap through leveraging Teijin's capabilities in health care, materials
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)